Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-28
2010-10-12
Duffy, Patricia A (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07811769
ABSTRACT:
This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.
REFERENCES:
patent: 4271140 (1981-06-01), Bunting
patent: 4474892 (1984-10-01), Murad et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 5213962 (1993-05-01), Van Nostrand et al.
patent: 5220013 (1993-06-01), Ponte et al.
patent: 5223482 (1993-06-01), Schilling, Jr. et al.
patent: 5234814 (1993-08-01), Card et al.
patent: 5262332 (1993-11-01), Selkoe
patent: 5387742 (1995-02-01), Cordell
patent: 5547841 (1996-08-01), Marotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5750349 (1998-05-01), Suzuki et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 6114133 (2000-09-01), Seubert et al.
patent: 6284221 (2001-09-01), Schenk et al.
patent: 6610493 (2003-08-01), Citron et al.
patent: 2003/0148392 (2003-08-01), Citron et al.
patent: 2004/0253643 (2004-12-01), Seubert et al.
patent: 2004/0265920 (2004-12-01), Seubert et al.
patent: 2005/0069968 (2005-03-01), Seubert et al.
patent: 705907 (1999-09-01), None
patent: 2205359 (2006-07-01), None
patent: 274 826 (1988-07-01), None
patent: 683 234 (1995-11-01), None
patent: 0 444 856 (1997-09-01), None
patent: 0 667 959 (2003-08-01), None
patent: 0 792 458 (2004-10-01), None
patent: 62-67297 (1987-11-01), None
patent: 4-252954 (1992-09-01), None
patent: 4-252955 (1992-09-01), None
patent: 4-252956 (1992-09-01), None
patent: WO 90/12870 (1990-11-01), None
patent: WO 90/12871 (1990-11-01), None
patent: WO 93/14200 (1993-07-01), None
patent: WO 94/17197 (1994-01-01), None
patent: WO 94/10569 (1994-05-01), None
patent: WO 96/15452 (1996-05-01), None
patent: WO 96/25435 (1996-08-01), None
patent: WO 97/48983 (1997-12-01), None
patent: WO 01/62284 (2001-08-01), None
patent: 03/051374 (2003-06-01), None
Nakamura (Ann Neurol, 36:903-911, 1994).
Pirttila et al (Journal of the Neurological Sciences, 127:90-95, 1994).
Tabaton et al (Neurology, 44(suppl 2): A371, Apr. 1994).
Assini et al, Neurology, 63:828-831, 2004; abstract.
Blasko et al, Neurobiology of Aging, 26:1135-1143, 2005; abstract.
Fukumoto et al (Arch Neurol. 60:958-964, 2003).
U.S. Appl. No. 60/186,295, Chain.
U.S. Appl. No. 09/649,891, filed Aug. 28, 2000, Schenk et al.
U.S. Appl. No. 08/466,554, filed Jun. 6, 1995, Seubert et al.
U.S. Appl. No. 08/419,008, filed Apr. 7, 1995, Seubert et al.
U.S. Appl. No. 07/965,972, filed Oct. 26, 1992, Schenk et al.
U.S. Appl. No. 07/911,647, filed Jul. 10, 1992, Schenk et al.
Andreasen et al., “β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease,”Peptides, 23:1205-1214 (2002).
Cai et al., :“Release of Excess Amyloid β Protein From a Mutant Amyloid β Protein Precursor,”Science, 259:514-516 (1993).
Conference Program for the 24th Annual Meeting of the Society of Neurosciences, Nov. 13-18, 1994.
European Search Report for Application No. EP 04077711.2 dated Feb. 9, 2005.
European Search Report for Application No. EP 95939892.6 dated Jan. 11, 1999.
Growdon et al., “Cerebrospinal Fluid Levels of Amyloid β- Protein are Independent of Apolipoprotein E Genotype and are Inversely Correlated With Severity of Dementia in Alzheimer's Disease,” Soc. Neurosci. Abstracts, 20(1-2):1058 (1994).
Jarrett et al., “The Carboxy Terminus of the β Amyloid Protein is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease,”Biochemistry, 32(18): 4693-4697 (1993).
Jensen et al., “Increased Cerebrospinal Fluid Tau in Patients with Alzheimer's Disease,”Neuroscience Letters, 186:189-191 (1995).
Lannfelt et al., “Disease Progression Correlates with Decreasing CSF β Amyloid in Alzheimer Patients With the Swedish APP 670/671 Mutation,”Neurobiology of Aging, 15(Suppl. 1):S79 (1994).
Pirttila et al., “Immunoreactivity Against Amyloid Beta Peptide (Aβ) is Decreased in the Cerebrospinal Fluid (CSF) from Patients with Alzheimer's Disease,”Neurology, 44 (Suppl 2):315P (1994).
Press Release, Mayo Research Group, Mayo Researchers Identify a Good Predictor for Those at Greater Risk for Alzheimer's Disease (Jun. 19, 2005).
Selkoe, Dennis J., “Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease,”TINS, 16(10): 403-409 (1993).
Shoji et al., “Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing,”Science, 258:126-129 (1992).
Society for Neuroscience Abstracts, vol. 20, Part 2 showing the date stamp for receipt by the British Library of May 1, 1995.
U.S. Appl. No. 10/964,484, Office Action mailed Jun. 29, 2009.
Allsop, D., “Monoclonal Antibodies Raised Against A Subsequence of Senile Plaque Core Protein React With Plaque Cores. Plaque Periphery and Cerebrovascular Amyloid in Alzheimer's Disease,”Neuroscience Letters, 68:252-256 (1986).
Anderson et al., “Exact Cleavage Site of Alzheimer Amyloid Precursor in Neuronal PC-12 Cells,”Neuroscience Letters, 128:126-128 (1991).
Barrow et al., “Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition,”Science, 253(5016):179-182 (1991).
Burdick et al., “Assembly and aggregation properties of synthetic Alzheimer's 4/β amyloid peptide antigens,”J. Biol. Chem., 267:546-555 (1992).
Chang et al., “β-Amyloid Protein in Cerebrospinal Fluid of Alzheimer Disease: Correlations with MMSE,”Neurology44(4 Sup. 2): (1994).
Chartier-Harlan et al., “Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene,”Nature, 353:844-846 (1991).
Chiu et al., “Reliability and Usefulness of a New Immmunochemical Assay for Alzheimer's Disease,”Archive of Neurology, 50(1):57-63 (1993).
Esch et al., “Cleavage of amyloid β peptide during constitutive processing of its precursor,”Science, 248:1122-1124 (1990).
Felsenstein et al., “Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing,”Alzheimer's and Parkinson's Diseases, pp. 401-409, Plenum Press, New York (1995).
Fukuchi et al., “Transgenic Animal Models for Alzheimer's Disease, Alzheimer's Disease Amyloid Precursor Proteins, Signal Transduction, and Neuronal Transplantation,”Annals of the New York Academy of Sciences, 695:217-227 (1993).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,”Nature, 373(6514);523-527 (1995).
Glenner et al., “Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein,”Biochem. Biophys. Res. Comm., 120:885-890 (1984).
Glenner et al., “Alzheimer's disease and Down's Syndrome: Sharing of unique cerebrovascular amyloid fibril protein,”Biochem. Biophys. Res. Comm., 122:1131-1135 (1984).
Goate et al., “Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease,”Nature, 349:704-706 (1991).
Goedert et al., “Multiple isoforms of human microtubule-associated protein tau:
Barbour Robin
Schenk Dale B.
Seubert Peter A.
Vigo-Pelfrey Carmen
Duffy Patricia A
Elan Pharmaceuticals Inc.
LandOfFree
Methods for aiding in the diagnosis of Alzheimer's disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for aiding in the diagnosis of Alzheimer's disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for aiding in the diagnosis of Alzheimer's disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228451